Summary

The EVA-AMI trial compared two intravenous glycoprotein IIb/IIIa inhibitors (GPI), eptifibatide and abciximab, as adjuncts to primary percutaneous coronary intervention (PCI) with respect to several measures of myocardial perfusion. The study represents the first head-to-head comparison of two GPIs in primary PCI for ST-elevation myocardial infarction.